Skip to main content
Clinical Trials/JPRN-UMIN000000757
JPRN-UMIN000000757
Completed
未知

Randomized controlled trial on effectiveness of ultrasonography in breast cancer screening(Japan Strategic Anti-Cancer Randomized Trial) - RCT on ultrasonography in breast cancer screening(J-START)

Division of Surgical Oncology, Graduate School of Medicine, TOHOKU UNIVERSITY0 sites100,000 target enrollmentJuly 1, 2007
ConditionsBreast Cancer

Overview

Phase
未知
Intervention
Not specified
Conditions
Breast Cancer
Sponsor
Division of Surgical Oncology, Graduate School of Medicine, TOHOKU UNIVERSITY
Enrollment
100000
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

A. Study Results 1. Standardization and propagation of breast cancer screening with ultrasonography: We formulated "Guidelines for Ultrasonography in Breast Cancer Screening" (Japanese and English versions) in 2007. Further, we developed a breast ultrasonography workshop in line with the Guidelines in order to disseminate the use of breast ultrasonography and provide education, training, and quality control for the institutions. 2. Implementation of a randomized controlled trial (RCT) to examine the effectiveness of ultrasonography: a. A total of 76,196 women in their 40's given informed-consent and participated in the RCT after the study were initiated. b. This is a nationwide study, with participation of 41 institutions from 23 prefectures. Study participation of the groups began in 2007, respectively, demonstrating the feasibility of large-scale clinical trials in Japan.

Registry
who.int
Start Date
July 1, 2007
End Date
March 1, 2015
Last Updated
2 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
Division of Surgical Oncology, Graduate School of Medicine, TOHOKU UNIVERSITY

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\. Women with history of breast cancer. 2\. Women with history of malignant disease other than breast cancer within 5 years. 3\. Women in severe condition, who are not expected to live for 5 years.

Outcomes

Primary Outcomes

Not specified

Similar Trials